BIO-AMD INCORPORATED (OTCMKTS:BIAD) Could Burn Your Long Portfolio After More Shorts

January 13, 2018 - By Ellis Scott

The stock of BIO-AMD INCORPORATED (OTCMKTS:BIAD) registered an increase of 2.82% in short interest. BIAD’s total short interest was 14,600 shares in January as published by FINRA. Its up 2.82% from 14,200 shares, reported previously. With 158,800 shares average volume, it will take short sellers 0 days to cover their BIAD’s short positions.

The stock decreased 2.08% or $0.00041 during the last trading session, reaching $0.01905. About 5,500 shares traded. Bio-AMD, Inc. (OTCMKTS:BIAD) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Bio-AMD, Inc., through its subsidiary, Bio AMD Holdings Limited, focuses on developing hand held electronic medical diagnostic devices. The company has market cap of $875,840. It offers point of care medical diagnostic products, including a disposable micro-fluidic test strip to measure prothrombin time/international normalized ratio through a POC blood coagulation monitoring device that enables patient based, anticoagulant drug therapy monitoring; and a digital strip reader to read various lateral flow based immunoassay diagnostic test strips in the areas of cardiac markers, infectious diseases, drugs of abuse, and female wellbeing. It currently has negative earnings. The firm also provides disposable test strip combining micro-fluidics and ‘lab-on-chip’ technology, which offers quantitative measurement into a immunoassay POC platform that detects nanoparticles through magnetic manipulation.

More important recent Bio-AMD, Inc. (OTCMKTS:BIAD) news were published by: which released: “Akers Biosciences Projects Explosive Growth From Its Monopoly Heparin Allergy Test” on May 21, 2015, also published article titled: “Global Point-of-Care Diagnostics Market 2017 – Forecast to 2023 – Research and …”, published: “Lateral Flow Technology And The Future Of Point Of Care Diagnostics, 2nd Edition” on March 11, 2014. More interesting news about Bio-AMD, Inc. (OTCMKTS:BIAD) was released by: and their article: “Japanese Healthcare Giant Invests In A Point-Of-Care Coagulation Diagnostic System” with publication date: March 03, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.